|
KMID : 0893420180190030393
|
|
Journal of Veterinary Science
2018 Volume.19 No. 3 p.393 ~ p.405
|
|
|
Toward the development of a one-dose classical swine fever subunit vaccine: antigen titration, immunity onset, and duration of immunity
|
|
Madera Rachel F.
Wang Lihua
Gong Wenjie
Burakova Yulia
Buist Sterling
Nietfeld Jerome
Henningson Jamie
Cino-Ozuna Ada G.
Tu Changchun
Shi Jishu
|
|
|
Abstract
|
|
|
|
Highly contagious classical swine fever (CSF) remains a major trade and health problem in the pig industry, resulting in large economic losses worldwide. In CSF-endemic countries, attenuated CSF virus (CSFV) vaccines have been routinely used to control the disease. However, eradication of CSFV in a geographical area would require permanent reduction to zero presence of the virus. It is therefore of paramount importance to develop a safe, potent, and non-infectious CSF vaccine. We have previously reported on a cost-effective CSF E2 subunit vaccine, KNB-E2, which can protect against CSF symptoms in a single dose containing 75 μg of recombinant CSFV glycoprotein E2. In this study, we report on a series of animal studies undertaken to elucidate further the efficacy of KNB-E2. We found that pigs vaccinated with a single KNB-E2 dose containing 25 μg of recombinant CSFV glycoprotein E2 were protected from clinical symptoms of CSF. In addition, KNB-E2-mediated reduction of CSF symptoms was observed at two weeks post-vaccination and the vaccinated pigs continued to exhibit reduced CSF clinical signs when virus challenged at two months and four months post-vaccination. These results suggest that KNB-E2 effectively reduces CSF clinical signs, indicating the potential of this vaccine for safely minimizing CSF-related losses.
|
|
|
KEYWORD
|
|
|
adjuvants, classical swine virus, subunit, vaccines
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|